Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 35279271

PD-1 blockade with pembrolizumab in classic or endemic Kaposi's sarcoma: a multicentre, single-arm, phase 2 study.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2022 Apr
First author
Delyon J

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships

    Authors and identifiers

    1. name
      Delyon J
      type
      Author
    2. name
      Biard L
      type
      Author
    3. name
      Renaud M
      type
      Author
    4. name
      Resche-Rigon M
      type
      Author
    5. name
      Le Goff J
      type
      Author
    6. name
      Dalle S
      type
      Author
    7. name
      Heidelberger V
      type
      Author
    8. name
      Da Meda L
      type
      Author
    9. name
      Toullec L
      type
      Author
    10. name
      Carcelain G
      type
      Author
    11. name
      Mourah S
      type
      Author
    12. name
      Caillat-Zucman S
      type
      Author
    Complete bibliographic record and source provenance
    authors
    1. name
      Delyon J
      type
      Author
    2. name
      Biard L
      type
      Author
    3. name
      Renaud M
      type
      Author
    4. name
      Resche-Rigon M
      type
      Author
    5. name
      Le Goff J
      type
      Author
    6. name
      Dalle S
      type
      Author
    7. name
      Heidelberger V
      type
      Author
    8. name
      Da Meda L
      type
      Author
    9. name
      Toullec L
      type
      Author
    10. name
      Carcelain G
      type
      Author
    11. name
      Mourah S
      type
      Author
    12. name
      Caillat-Zucman S
      type
      Author
    bibliography ids
    1. nci-bib-906c382403d7e2f70ada3a34
    book metadata
    content sha256
    16d2cfad7a7a00541d8c7a02668b91cb13e66cf9eef4580886740de38e073ab3
    document type
    citation
    dois
    1. 10.1016/S1470-2045(22)00097-3
    electronic publication date
    display
    2022 Mar 10
    precision
    day
    year
    2022
    evidence scope
    bibliographic_metadata_only
    id
    pubmed:35279271
    immutable id
    pubmed:35279271@16d2cfad7a7a00541d8c7a02668b91cb13e66cf9eef4580886740de38e073ab3
    journal
    abbreviation
    Lancet Oncol
    issn electronic
    1474-5488
    issn print
    1470-2045
    issue
    4
    name
    The Lancet. Oncology
    nlm unique id
    100957246
    pages
    491-500
    volume
    23
    languages
    1. eng
    notices
    absence is not clearance
    true
    has correction metadata
    false
    has expression of concern metadata
    false
    has retraction in link
    false
    pubmed marks article retracted
    false
    pubmed marks retraction notice
    false
    relationships
      outcomes validated
      false
      pmid
      35279271
      provenance
      batch id
      3f4d1914d2afe41e9e70
      provider
      NCBI PubMed ESummary
      record sha256
      16e50b2cd73aeb2aa5f32d792f509662b44cd81b631f3c605aa7b42e2e791a14
      response sha256
      0ceeb248a527e54c6f72dd28d20f7abec08a973fe2e10de00bede4895add09e7
      retrieved at
      2026-09-09T23:48:06.522634+00:00
      publication date
      display
      2022 Apr
      precision
      month
      year
      2022
      publication types
      1. Clinical Trial, Phase II
      2. Journal Article
      3. Multicenter Study
      4. Research Support, Non-U.S. Gov't
      record status
      PubMed - indexed for MEDLINE
      schema version
      1.0
      source url
      https://pubmed.ncbi.nlm.nih.gov/35279271/
      title
      PD-1 blockade with pembrolizumab in classic or endemic Kaposi's sarcoma: a multicentre, single-arm, phase 2 study.

      Preserved source evidence · Not medical advice